Media

News

Are you a media representative looking for content on Bayer? This section provides access to media releases as well as feeds from our social media channels.

October 23, 2020

Finerenone significantly reduced renal and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes

• Finerenone is a first-in-class investigational non-steroidal, selective mineralocorticoid receptor (MR) antagonist that demonstrated renal and cardiovascular benefits in patients with chronic kidney disease and type 2 diabetes • Finerenone specifically addresses MR overactivation, a key driver of disease progression • Despite guideline-directed therapies, patients with chronic kidney disease and type 2 diabetes remain at high risk of progression to kidney failure and cardiovascular events • Results from the FIDELIO-DKD study were simultaneously published in the New England Journal of Medicine Read more
September 29, 2020

New data reinforce strong clinical profile of VITRAKVI® for patients of all ages with TRK Fusion Cancer including lung and thyroid tumours

• 78% overall response rate (ORR) and median progression-free survival (PFS) of more than 3 years (36.8 months) demonstrate extended benefit in updated data set of 175 adults and children • Majority of adverse events were grade 1 or 2; no new safety signals identified • Consistently high ORRs shown in lung and thyroid data subsets (71 and 75%, respectively), as well as long durability (estimated duration of response at 12 months of 88% and 95%, respectively) • Among patients from integrated dataset with brain metastases (n=14), ORR was 71%, and 57% in patients with lung cancer with brain metastases (n=7) Read more
September 25, 2020

After the revolution: The pill turns 60 and Bayer sets new goal to help 100 million women

Read more
September 22, 2020

Canadian Students Receive $90,000 in Support from Bayer Fund’s Opportunity Scholarship

Read more
September 01, 2020

Bayer launches Proline® GOLD for premium protection against sclerotinia in canola

Read more
August 14, 2020

Bayer to acquire UK-based biotech KaNDy Therapeutics Ltd.

• Further expansion of Bayer’s drug development pipeline in Women’s Healthcare • Innovative non-hormonal oral compound NT-814 being studied to alleviate menopausal symptoms • Development compound recently completed Phase IIb • Reinforces Bayer’s position in Women’s Healthcare Read more
August 04, 2020

Bayer’s finerenone meets primary endpoint in Phase III FIDELIO-DKD renal outcomes study in patients with chronic kidney disease and type 2 diabetes

• Finerenone significantly reduced the combined primary endpoint of chronic kidney disease progression, kidney failure or kidney death versus placebo when added to standard of care • Finerenone significantly reduced the combined key secondary endpoint of cardiovascular death or non-fatal cardiovascular events • Chronic kidney disease impacts 4 in 10 patients with type 2 diabetes and is a deadly condition that is underrecognized • Finerenone is the first investigational non-steroidal, selective mineralocorticoid receptor antagonist to demonstrate renal and cardiovascular benefits in patients with chronic kidney disease and type 2 diabetes Read more
July 23, 2020

Bayer Inc. launches FastTRK, a complimentary clinical testing program for the diagnosis of NTRK gene fusions in TRK fusion cancer patients in Canada

Read more
June 24, 2020

Bayer announces agreements to resolve major legacy Monsanto litigation

Company will make a total payment of $10.1 billion to $10.9 billion (€9.1 billion to €9.8 billion) to resolve current and address potential future Roundup™ litigation/ • Company also resolves dicamba drift litigation for payment of up to $400 million and most PCB water litigation exposure for payment of approximately $820 million/ • Funding sourced from free cash flow and Animal Health divestment /• Bayer is well positioned to deliver science-based solutions to meet global health, nutrition needs Read more
June 17, 2020

Non-metastatic castration resistant prostate cancer treatment NUBEQA® (darolutamide) significantly improves overall survival with a favourable safety profile in men with non-metastatic prostate cancer

Read more